Extracorporeal LDL cholesterol elimination (25 years of experience in CZ)

Stoffel, 1981, Application of specific extracorporeal removal of low density lipoprotein in familial hypercholesterolemia, Lancet, 318, 1005, 10.1016/S0140-6736(81)91213-7 Borberg, 2009, 28 years of LDL-apheresis: a review of experience, Transfus Apher Sci, 41, 49, 10.1016/j.transci.2009.05.013 Bláha, 2003, Extracorporeal LDL-cholesterol elimination in the treatment of severe familial hypercholesterolemia, Acta Med (Hradec Králové), 46, 3, 10.14712/18059694.2019.1 Thompson, 2003, LDL apheresis, Atherosclerosis, 167, 1, 10.1016/S0021-9150(02)00251-4 Borberg, 2006, Quo vadis, haemapheresis. Current developments in haemapheresis, Transf Apher Sci, 34, 51, 10.1016/j.transci.2005.11.001 Richter, 1999, Three low density lipoprotein apheresis techniques in treatment of patients with hypercholesterolemia: a long-term evaluation, Ther Apher Dial, 3, 203, 10.1046/j.1526-0968.1999.00154.x Schuff-Werner, 2003, Clinical long-term results of H.E.L.P-apheresis, Z Kardiol, III28 Bambauer, 2003, Low-density lipoprotein apheresis: an overview, Therap Apher Dial, 7, 391, 10.1046/j.1526-0968.2003.00070.x Pták J. Immunoadsorption in the therapy of myasthenia gravis. (In Czech.) Praha; Galén, 2004:1-128. Williams, 1993, Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics, Am J Cardiol, 72, 171, 10.1016/0002-9149(93)90155-6 Šamánek, 1997, Cholesterol and triglyceride levels and their development. Čas Lék, Čes, 136, 380 Klingel, 2005, Rheopheresis in patients with critical limb ischemia – results of an open label prospective pilot trial, Ther Apher Dial, 9, 473, 10.1111/j.1744-9987.2005.00276.x Bláha, 2007, Safety and tolerability of long lasting LDL-apheresis in familial hyperlipoproteinemia, Ther Apher Dial, 11, 9, 10.1111/j.1744-9987.2007.00450.x Blaha M, Strasova A, Ungerman L, Blazek M, Blaha V, Maly J, Masin V. Significance of Non-Invasive Cardiovascular Examinations for the Evaluation of extracorporeal LDL-Cholesterol Elimination Efficacy. Abstract. Transfusion Medicine and Hemotherapy 2008;35. Suppl. 1:80. ISSN 1660-3796. Bláha, 2005, Optimization of the therapeutic procedure during LDL- apheresis – a computerized model, Transf Sci, 32, 149 Bláha, 2003, Adhesive selectin molecules during extracorporeal cholesterol elimination, The Hematology Journal, 4, 23 Bláha, 2008, Elevated serum soluble endoglin (sCD105) decreased during extracorporeal elimination therapy for familial hypercholesterolemia, Atherosclerosis, 197, 264, 10.1016/j.atherosclerosis.2007.04.022 Blaha, 2004, Activity of Thrombocytes as a Marker of Sufficient Intensity of LDL-apheresis in Familial Hypercholesterolaemia, Transfus Apher Sci, 30, 83, 10.1016/j.transci.2003.11.002